Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis

Abstract

Objective: To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD.

Methods: We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study.

Results: We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10(-16), r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex.

Conclusions: Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.

© 2014 American Academy of Neurology.

Figures

Figure 1. Age at symptom onset by mutated gene

Age at symptom onset for all affected individuals are shown grouped by the gene affected by their autosomal dominant Alzheimer disease mutation, with APP mutations having an additional subclass for gene duplications. APP = amyloid precursor protein; PS1 = presenilin 1; PS2 = presenilin 2.

Figure 2. Individual age at symptom onset vs measures of family onset history

The actual age at symptom onset for each affected individual is shown on the y-axis, plotted against values predicted from family history on the x-axis. (A) Each individual's age at onset vs the reported age at onset of their affected parent. (B) Each individual's age at onset vs the mean age at onset for all other individuals in their extended family. (C) Each individual's age at onset vs the mean age at onset for all other individuals sharing the same autosomal dominant Alzheimer disease mutation type. Plot points for each individual are colored according to their study of origin, as shown in the legend at the upper right. Jitter was added to the x- and y-axes for easier visualization. Regression lines and adjusted r2 values showing correlations between individual age at onset and each of these family history measures are displayed on the respective figures. DIAN = Dominantly Inherited Alzheimer Network.

Figure 3. Age at onset differences by APOE genotype

For affected individuals with known APOE genotype, the difference between each individual's actual age at onset and the mean age at onset of all others sharing the same autosomal dominant Alzheimer disease mutation type is plotted on the y-axis.

Figure 4. Age at symptom onset vs disease course in years

(A) For all individuals with known ages of symptom onset and death, age at symptom onset is plotted against disease course in years, estimated as the total time from symptom onset to death. Jitter was added to the x- and y-axes. A nonparametric smoothing function (LOESS) is shown in blue. Dashed red lines indicate median age at symptom onset and median survival from symptom onset in sporadic Alzheimer disease based on published data. (B) Individuals are shown partitioned into 3 groups by age at symptom onset.